Literature DB >> 22961139

Drug pipeline is flush with new options for chronic constipation.

Elie Dolgin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22961139     DOI： 10.1038/nm0912-1308

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  5 in total

1.  Two randomized trials of linaclotide for chronic constipation.

Authors:  Anthony J Lembo; Harvey A Schneier; Steven J Shiff; Caroline B Kurtz; James E MacDougall; Xinwei D Jia; James Z Shao; Bernard J Lavins; Mark G Currie; Donald A Fitch; Brenda I Jeglinski; Paul Eng; Susan M Fox; Jeffrey M Johnston
Journal:  N Engl J Med       Date:  2011-08-11       Impact factor: 91.245

2.  Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation.

Authors:  W D Chey; D A Drossman; J F Johanson; C Scott; R M Panas; R Ueno
Journal:  Aliment Pharmacol Ther       Date:  2012-01-18       Impact factor: 8.171

3.  Scintigraphic biomarkers for colonic dysmotility.

Authors:  M Camilleri
Journal:  Clin Pharmacol Ther       Date:  2010-04-21       Impact factor: 6.875

4.  Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain.

Authors:  H Eutamene; S Bradesi; M Larauche; V Theodorou; C Beaufrand; G Ohning; J Fioramonti; M Cohen; A P Bryant; C Kurtz; M G Currie; E A Mayer; L Bueno
Journal:  Neurogastroenterol Motil       Date:  2009-08-25       Impact factor: 3.598

5.  A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation.

Authors:  William D Chey; Michael Camilleri; Lin Chang; Leif Rikner; Hans Graffner
Journal:  Am J Gastroenterol       Date:  2011-05-24       Impact factor: 10.864
  5 in total
  3 in total

Review 1.  Prucalopride: For functional constipation only?

Authors:  M Bellini; D Gambaccini; G Bassotti
Journal:  Tech Coloproctol       Date:  2016-05-12       Impact factor: 3.781

2.  Cysteine pseudoprolines for thiol protection and peptide macrocyclization enhancement in Fmoc-based solid-phase peptide synthesis.

Authors:  Tobias M Postma; Fernando Albericio
Journal:  Org Lett       Date:  2014-03-11       Impact factor: 6.005

3.  Immobilized N-chlorosuccinimide as a friendly peptide disulfide-forming reagent.

Authors:  Tobias M Postma; Fernando Albericio
Journal:  ACS Comb Sci       Date:  2014-03-31       Impact factor: 3.784
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.